Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
about
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor.Global Manufacturing of CAR T Cell Therapy.10-year stability of clinical-grade serum-free γ-retroviral vector-containing medium.
P2860
Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
@ast
Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
@en
Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
@nl
type
label
Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
@ast
Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
@en
Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
@nl
prefLabel
Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
@ast
Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
@en
Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
@nl
P2093
P2860
P356
P1433
P1476
Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
@en
P2093
B A Luider
C H J Lamers
J W Gratama
P van Elzakker
S C L van Steenbergen
S Sleijfer
P2860
P2888
P304
P356
10.1038/SJ.CGT.7701114
P577
2008-01-18T00:00:00Z